##  [FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US](/us-en/news/media-releases/fda-approves-novartis-tobi-podhalertm-certain-cystic-fibrosis-patients-first-and-only-dry-powder-inhaled-antibacterial-us-0 "FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US") 

  Mar 22, 2013